A Discussion on Strategies for New Therapies and Evolving Care in Chronic Lymphocytic Leukemia (CLL) (Participant)

Credit Available: CABRN, CME

 

Enroll in this Course

FREE

access until December 8, 2026 12:00 am

 

Enroll Now

Activity Description

This recorded webinar will provide a clinical update on chronic lymphocytic leukemia (CLL). Expert faculty will review the latest therapies, including BTK inhibitors and CAR T-cell therapy, share guidance on patient selection, and discuss strategies for treatment management, toxicity monitoring, and long-term survivorship care.

Time to Complete Activity: 1.0 hours

This course is available from:

December 9, 2025 until December 8, 2026

Course Instructors

Inhye Ahn, MD Speaker

Associate Director, Chronic Lymphocytic Leukemia Center, Senior Physician, Assistant Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA

Corinne Hoffman, MS, APRN-CNP, AOCNP Speaker

Nurse Practitioner – Hematology Oncology, The James Comprehensive Cancer Center, The Ohio State University, Columbus, OH

Kerry Rogers, MD  Speaker

Associate Professor,  Division of Hematology, Department of Internal Medicine, The James Comprehensive Cancer Center,  The Ohio State University, Columbus, OH

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, PAs, NPs, nurses, and other healthcare professionals engaged in the care of patients with chronic lymphocytic leukemia (CLL).

Learning Objectives
After completing this activity, the participant should be better able to:

• • Explain treatment options including an overview of the latest developments in therapy
  • Identify patients who are candidates for newly approved therapies including BTK inhibitors, alone or in combination, and CAR T-cell therapy
  • Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects
  • Discuss long-term follow up and survivorship care planning

Accreditation, Credit and Support

In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Medical Learning Institute Inc (MLI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nursing Credit Designation

Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.

ILNA Recertification Points

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care Continuum (OCN, CBCN, CPHON AOCNP) 0.75*, Foundations of Transplant (BMTCN) 0.5*, Late Post-Transplant Management and Education (BMTCN) 0.25*, Quality of Life (BMTCN) 0.25*, Transplant Process and Infusion (BMTCN) 0.75*, Treatment (OCN, CBCN, AOCNP, CPHON) 0.75*.

Total Points: 1

*Note that the course content applies to multiple subject areas across multiple credentials. The numerical value indicated above is the maximum number of points that can be claimed in each subject area. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential you are renewing. Please also note that nurses’ individual learning plans are linked to their credential’s test blueprint (content outline).
Current ONCC test content outlines can be found on the ONCC website:
OCN® | https://www.oncc.org/files/2022OCNOutline.pdf   
CPHON® | https://www.oncc.org/files/CPHONTestContentOutline.pdf  
CBCN® | https://www.oncc.org/files/2022CBCNOutline.pdf   
BMTCN® | https://www.oncc.org/files/2022BMTCNOutline.pdf  
AOCNP® | https://www.oncc.org/files/2020AOCNPTestContentOutline.pdf

Providers

This activity is provided by Blood Cancer United and Medical Learning Institute Inc.

         

Support Statement

This activity is supported by independent medical education grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.

Disclosure of Conflicts of Interest Policy

Blood Cancer United and Medical Learning Institute Inc, are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, Blood Cancer United and MLI require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to Blood Cancer United and MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.

Faculty Disclosures

Inhye Ahn, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AstraZeneca, BeOne, Lilly
Research Funding/Support: BeOne, Genentech, Lilly

Lauren Berger, MPH, has a financial interest/relationship or affiliation in the form of:
Stock Ownership with Bristol Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Organon & Co., Pfizer Inc., and Viatris Inc.

Corinne Hoffman, MS, APRN-CNP, AOCNP, has no relevant financial relationships with ineligible companies to disclose for this educational activity.

Kerry Rogers, MD, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: AbbVie, Alpine Immune Sciences, AstraZeneca, BeOne Medicines, Genentech, Janssen, Loxo@Lilly
Research Support (funding for clinical trials paid to institution): AbbVie, AstraZeneca, Genentech, Loxo@Lilly

All of the relevant financial relationships of individuals for this activity have been mitigated.

Planning Committee and Content/Peer Reviewers

The planners and content/peer reviewers from Blood Cancer United and Medical Learning Institute Inc do not have any relevant financial relationships to disclose with ineligible companies unless listed below.

All of the relevant financial relationships of individuals for this activity have been mitigated.

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the accredited CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

About this Activity

Blood Cancer United and Medical Learning Institute Inc are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Blood Cancer United and Medical Learning Institute Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit. You will receive your certificate from Medical Learning Institute Inc.

For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.

If you have questions regarding your certificate, please contact Nicole Dane at ndane@mlieducation.org 

For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at profeducation@bloodcancerunited.org.